Tianfeng Securities released a research report on April 18 stating that it gave Xintian Pharmaceutical (002873.SZ) an increase in holdings rating. The main reasons for the rating include: 1) revenue pressure on core products; 2) marketing system reforms are showing initial results, and costs have been optimized; 3) epitaxial expansion is expected to form a “traditional Chinese medicine+chemical medicine” dual-track pattern. (Mainichi Keizai Shimbun)
天风证券4月18日发布研报称，给予新天药业（002873.SZ）增持评级。评级理由主要包括：1）核心产品收入承压；2）营销系统改革初见成效，费用有所优化；3）外延拓展，有望形成“中药+化药”双赛道格局。（每日经济新闻）
Tianfeng Securities released a research report on April 18 stating that it gave Xintian Pharmaceutical (002873.SZ) an increase in holdings rating. The main reasons for the rating include: 1) revenue pressure on core products; 2) marketing system reforms a
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.